Genmab Cash Pile To Grow With Another Darzalex OK

The Danish biotech will be getting more revenues from its J&J-partnered multiple myeloma blockbuster following a new US approval. Analysts are impressed with the way Genmab is spending the money.

Safe_Money
Kroner keeps coming in for Genmab • Source: Shutterstock

Genmab AS's coffers are set to swell again after US regulators granted another approval for Darzalex, further cementing the Johnson & Johnson-partnered drug's dominant position in the multiple myeloma field.

Following a priority review granted in May, the US Food and Drug Administration has approved Darzalex (daratumumab) in combination with...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip